Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells-Reference-Cited by-同舟云学术

Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells

Published:2016-10-27 Issue: Volume:7 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Sánchez-Martínez Diego,Lanuza Pilar M.,Gómez Natalia,Muntasell Aura,Cisneros Elisa,Moraru Manuela,Azaceta Gemma,Anel Alberto,Martínez-Lostao Luis,Villalba Martin,Palomera Luis,Vilches Carlos,García Marco José A.,Pardo Julián

Funder

SUDOE

Fondo Social Europeo (FSE)

Fundacion ARAID

Fondation de France

Ministerio de Economía y Competitividad

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference69 articles.

1. Chronic lymphocytic leukemia;Rozman;N Engl J Med,1995

2. From pathogenesis to treatment of chronic lymphocytic leukaemia;Zenz;Nat Rev Cancer,2010

3. Chronic lymphocytic leukemia;Chiorazzi;N Engl J Med,2005

4. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia;Keating;J Clin Oncol,2005

5. Genomic aberrations and survival in chronic lymphocytic leukemia;Dohner;N Engl J Med,2000

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The arming of NK cells with Fc-engineered rituximab confers them specificity against CD20-expressing cells;2024-03-11

2. Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade?;Acta Haematologica;2023-10-09

3. Dynamic Changes in miRNA Expression during the Generation of Expanded and Activated NK Cells;International Journal of Molecular Sciences;2023-08-31

4. Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential;Cancers;2022-11-24

5. Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy;Blood Advances;2022-10-18